| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 3, 2019Patent allowances cover various aspects of the Company's phage program and lead product candidate, AP-SA01
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
May 28, 2019Armata's bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection
Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
-
May 9, 2019Shares of the combined company to commence trading on the NYSE American exchange under the new symbol "ARMP" on May 10, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
-
May 8, 2019
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
-
Apr 2, 2019C3J’s pending merger with AmpliPhi Biosciences, which will create a clinical-stage phage leader, is on track to close in May 2019
LOS ANGELES, Calif., April 2, 2019 — C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on...